Press "Enter" to skip to content

LSS 101: Developing a New SARS-CoV-2 Vaccine; Expression of Host Cell Genes That Modulate SARS-CoV-2 Entry

In today’s episode, we continue our series of interviews with scientists who have decided to use their expertise in their respective fields to help further research into the biology of SARS CoV-2, the virus that causes COVID-19.

First off, you’ll hear Esther Racoosin’s interview of Dr. Matthew DeLisa, a Professor of Engineering at Cornell University.  For 4 years, his laboratory has been using bacterial Outer Membrane Vesicle (OMV) technology to develop a universal influenza vaccine. Recently, DeLisa’s lab has been using that to design a vaccine for SARS-CoV-2.

To learn more about Dr. DeLisa’s research, visit


In today’s second interview, Esther speaks with Dr. Cedric Feschotte, Professor in the Cornell Department of Molecular Biology and Genetics.  Researchers in Dr. Feschotte’s lab study how mobile DNA elements, such as transposons and endogenous viruses move around in genomes. 

Following the start of the COVID-19 pandemic, he and post-doctoral fellow Dr. Manu Singh and Dr. Vikas Bansal of the Max Planck Institute in Tubingen, Germany, began study studying host cell expression of genes called SCARFs.  That acronym stands for SARS CoV-2 and Coronavirus-Associated Receptors and factors.   SCARFs include cellular factors both facilitating and restricting viral entry.

To learn more about SCARFs, visit

To find out more about research in Dr. Feschotte’s lab, visit

Producer: Liz Mahood

Associate Producer: Esther Racoosin

Interviews of Dr. Matt DeLisa and Dr. Cedric Feschotte: Esther Racoosin

Music: Joe Lewis; Blue Dot Sessions

Leave a Reply

Your email address will not be published. Required fields are marked *